Fu YG - Search Results

1

Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells.

Dong XD, Zhang M, Cai CY, Teng QX, Wang JQ, Fu YG, Cui Q, Patel K, Wang DT, Chen ZS. Dong XD, et al. Among authors: fu yg. Front Pharmacol. 2022 Feb 23;13:843829. doi: 10.3389/fphar.2022.843829. eCollection 2022. Front Pharmacol. 2022. PMID: 35281897 Free PMC article.

2

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells.

Wu ZX, Peng Z, Yang Y, Wang JQ, Teng QX, Lei ZN, Fu YG, Patel K, Liu L, Lin L, Zou C, Chen ZS. Wu ZX, et al. Among authors: fu yg. Front Oncol. 2020 May 12;10:674. doi: 10.3389/fonc.2020.00674. eCollection 2020. Front Oncol. 2020. PMID: 32477940 Free PMC article.

3

Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells.

Wu ZX, Yang Y, Wang JQ, Zhou WM, Chen J, Fu YG, Patel K, Chen ZS, Zhang JY. Wu ZX, et al. Among authors: fu yg. Front Pharmacol. 2021 Jan 14;11:615824. doi: 10.3389/fphar.2020.615824. eCollection 2020. Front Pharmacol. 2021. PMID: 33519482 Free PMC article.

4

BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation.

Rathod D, Fu Y, Patel K. Rathod D, et al. Eur J Pharm Sci. 2019 Oct 1;138:105039. doi: 10.1016/j.ejps.2019.105039. Epub 2019 Aug 5. Eur J Pharm Sci. 2019. PMID: 31394259

5

Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.

Fu Y, Rathod D, Patel K. Fu Y, et al. Exp Cell Res. 2020 Nov 1;396(1):112275. doi: 10.1016/j.yexcr.2020.112275. Epub 2020 Sep 6. Exp Cell Res. 2020. PMID: 32898554

6

Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable' c-Myc for the treatment of pancreatic cancer.

Saraswat A, Patki M, Fu Y, Barot S, Dukhande VV, Patel K. Saraswat A, et al. Nanomedicine (Lond). 2020 Aug;15(18):1761-1777. doi: 10.2217/nnm-2020-0156. Epub 2020 Jul 23. Nanomedicine (Lond). 2020. PMID: 32698663

7

Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma.

Fu Y, Saraswat A, Wei Z, Agrawal MY, Dukhande VV, Reznik SE, Patel K. Fu Y, et al. Pharmaceutics. 2021 Jul 1;13(7):1005. doi: 10.3390/pharmaceutics13071005. Pharmaceutics. 2021. PMID: 34371697 Free PMC article.

8

EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF^V600E Mutated Parent- and Vemurafenib-Resistant Melanoma.

Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K. Fu Y, et al. Pharmaceutics. 2019 Oct 1;11(10):504. doi: 10.3390/pharmaceutics11100504. Pharmaceutics. 2019. PMID: 31581483 Free PMC article.

9

Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma.

Saraswat A, Vartak R, Hegazy R, Fu Y, Rao TJR, Billack B, Patel K. Saraswat A, et al. Biomed Pharmacother. 2023 Dec;168:115754. doi: 10.1016/j.biopha.2023.115754. Epub 2023 Oct 21. Biomed Pharmacother. 2023. PMID: 37871557 Free article.

10

Multi-dose oral abuse deterrent formulation of loperamide using hot melt extrusion.

Nukala PK, Palekar S, Patki M, Fu Y, Patel K. Nukala PK, et al. Int J Pharm. 2019 Oct 5;569:118629. doi: 10.1016/j.ijpharm.2019.118629. Epub 2019 Aug 16. Int J Pharm. 2019. PMID: 31425818

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters